Although the exact mechanism remains unclear, it has been proposed that dupilumab's inhibition of IL-4 and IL-13 may indirectly downregulate IL-6-driven Th2 responses, which are elevated in patients with lichen planus and may contribute to disease persistence [7]. This evidence concerns the gene IL6 and lichen planus.